MONITORING OF EGFR MUTATIONS IN THE CIRCULATING TUMOR DNA FROM BLOOD PLASMA OF PATIENTS WITH NON-SMALL CELL LUNG CANCER
Activating mutations of EGFR are associated with sensitivity of non-small cell lung cancer (NSCLC ) to tyrosine kinase inhibitors (TKI). Liquid biopsy using circulating cell-free tumor DNA (cfDNA) is proposed in cases when formalin fixed paraffin embedded (FFPE) tumor tissue is not available and for...
Saved in:
Main Authors: | V. A. Shamanin, I. V. Karpov, P. А. Gervas, N. V. Cherdyntseva, E. I. Simolina, V. V. Kozlov, S. P. Kovalenko |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Russian Academy of Sciences, Tomsk National Research Medical Center
2018-11-01
|
Series: | Сибирский онкологический журнал |
Subjects: | |
Online Access: | https://www.siboncoj.ru/jour/article/view/858 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Lung Adenocarcinoma with EGFR Exon 20 H773_V774delinsLM Mutation
Sensitive to Furmonertinib: A Case Report
by: Rongzhen LI, et al.
Published: (2025-06-01) -
Assessment of the effectiveness of surgical resections following tyrosine kinase inhibitor therapy in patients with EGFR-mutated stage III–IV lung adenocarcinoma
by: E. V. Levchenko, et al.
Published: (2023-02-01) -
First‐Line Osimertinib for EGFR‐Mutated Squamous Cell Lung Carcinoma: A Case Report
by: Yugo Matsumura, et al.
Published: (2025-07-01) -
Response of EGFR-mutated pulmonary pleomorphic carcinoma to pembrolizumab
by: Yuki Hatakeyama, et al.
Published: (2025-01-01) -
BRAF Fusion as Resistance Mechanism to Osimertinib in EGFR-Mutated NSCLC: A Case Report and Review of Literature
by: Marianna Peroni, MD, et al.
Published: (2025-08-01)